Efficacy and Cost of Ampicillin‐Sulbactam and Ticarcillin‐Clavulanate in the Treatment of Hospitalized Patients with Bacterial Infections

McKinnon, Peggy S.; Neuhauser, Melinda M.

doi:10.1592/phco.19.9.724.31537

Cited by 11 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical usefulness of this antibiotic therapy for SSTIs has been confirmed by more recent studies (mostly comparative, prospective and randomised) [52][53][54][55][56][57][58] (Table 5). AMS, in doses ranging from 4 g to 12 g daily, has comparable efficacy to clindamycin, cefoxitin, ticarcillin/clavulanic acid (retrospective study) and piperacillin/tazobactam, with clinical efficacy >80% and eradication rates of 41-100%.…”

Section: Skin and Soft-tissue Infectionsmentioning

confidence: 82%

Rational antibiotic therapy and the position of ampicillin/sulbactam

Lode

2008

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Skin and Soft-tissue Infectionsmentioning

confidence: 82%

Rational antibiotic therapy and the position of ampicillin/sulbactam

Lode

2008

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…The corre-spondingratesofbacteriologicalefficacywere62and 71%. 31 These data suggest that Ampicillin/Sulbactam is as effective as another β-lactam/β-lactamase inhibitor combination in the treatment of lower respiratory tract infection.…”

Section: Lower Respiratory Tract Infections and Aspiration Pneumoniamentioning

confidence: 89%

“…Ampicillin/sulbactam (2-12 gr./day), followed by oral sultamicillin in some cases, has been compared with imipenem/cilastatin, second and third generation cephalosporins, ticarcillin/clavulanic, clindamycin(withorwithoutcephalosporin),ormoxifloxacin for the treatment of community-or hospital-acquired lower respiratory tract infections without significantly differences. [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] In the review made by Lode 6 in 2001 on the role of Ampicillin/Sulbactam in the treatment of bacterial respiratory tract infections in adult patients, based on 20 researches comparatives and two meta-analyses published in the 1980s and 1990s, the clinical success rates were in the range of 84%-100% and bacteriological eradication rates ranged from 44% to 100%. In recent studies (mainly comparative, prospective and randomised) the clinical efficacy (cure or improvement) rates are ranged from62%to100%andbacteriologicalefficacyrates from 58%-100%.…”

Section: Lower Respiratory Tract Infections and Aspiration Pneumoniamentioning

confidence: 99%

Ampicillin/Sulbactam in Combination: A Review of its Use in the Treatment of Severe Bacterial Infections

2010

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Ampicillin/Sulbactam is a combination of antibiotics made up of ampicillin, a betalactam and Sulbactam, a betalactamase inhibitor introduced in the eighties. The most frequent used combination is Ampicillin/Sulbactam (ratio 2:1) although the two agents are not synergetic. Ampicillin/Sulbactam has a wide range of antibacterial activity that includes Gram-positive and Gram-negative aerobic and anaerobic bacteria. However, the drug is not active against Pseudomonas aeruginosa and pathogens producing extended-spectrum β-lactamases. The combination could be considered particularly active against Acinetobacter baumannii infections due to the intrinsic activity of Sulbactam. In clinical trials, sultamicillin has proved clinically and bacteriologically effective against a severe bacterial infections, including mild upper and lower respiratory tract infections, meningitis, intra-abdominal, diabetic foot and skin and soft tissue infections, etc. Furthermore, adverse effects rarely occur with the diarrhoea to represent the most commonly reported. Moreover, it seems to represent the alternative of choice for the treatment of A. baumannii infections for carbapenem-resistant strains in the nosocomial setting. This review focuses on the efficacy of the β-lactam ampicillin co-administered with the β-lactamase inhibitor sulbactam, parenterally (Ampicillin/Sulbactam), for the treatment of bacterial infections.

show abstract

“…A retrospective observational study found comparable clinical response rate between ampicillin-sulbactam and ticarcillin-clavulanate (84.3% vs 77.5%) among hospitalized patients with infections including cIAIs and cUTIs. 23 Data on ICU admission and severity of infection were unavailable.…”

Section: Methodsmentioning

confidence: 99%

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients

Gatti¹,

Viaggi²,

Rossolini³

et al. 2021

IDR

View full text Add to dashboard Cite

Prompt implementation of appropriate targeted antibiotic therapy represents a valuable approach in improving clinical and ecological outcome in critically septic patients. This multidisciplinary opinion article focused at developing evidence-based algorithms for targeted antibiotic therapy of bloodstream (BSIs), complicated urinary tract (cUTIs), and complicated intrabdominal infections (cIAIs) caused by Enterobacterales . The aim was to provide a guidance for intensive care physicians either in appropriately placing novel antibiotics or in considering strategies for sparing the broadest-spectrum antibiotics. A multidisciplinary team of experts (one intensive care physician, one infectious disease consultant, one clinical microbiologist and one MD clinical pharmacologist), performed several rounds of assessment to reach agreement in developing six different algorithms according to the susceptibility pattern (one each for multi-susceptible, extended-spectrum beta-lactamase-producing, AmpC beta-lactamase-producing, Klebsiella pneumoniae carbapenemase (KPC)-producing, OXA-48-producing, and Metallo-beta-lactamase (MBL)-producing Enterobacterales ). Whenever multiple therapeutic options were feasible, a hierarchical scale was established. Recommendations on antibiotic dosing optimization were also provided. In order to retrieve evidence-based support for the therapeutic choices proposed in the algorithms, a comprehensive literature search was performed by a researcher on PubMed-MEDLINE from inception until March 2021. Quality and strength of evidence was established according to a hierarchical scale of the study design. Only articles published in English were included. It is expected that these algorithms, by allowing prompt revision of antibiotic regimens whenever feasible, appropriate place in therapy of novel beta-lactams, implementation of strategies for sparing the broadest-spectrum antibiotics, and pharmacokinetic/pharmacodynamic optimization of antibiotic dosing regimens, may be helpful either in improving clinical outcome or in containing the spread of antimicrobial resistance.

show abstract

Efficacy and Cost of Ampicillin‐Sulbactam and Ticarcillin‐Clavulanate in the Treatment of Hospitalized Patients with Bacterial Infections

Abstract: Ampicillin-sulbactam provides effective coverage for patients with the above infections and is as effective as the broader-spectrum agent.

Cited by 11 publications

References 19 publications

Rational antibiotic therapy and the position of ampicillin/sulbactam

Rational antibiotic therapy and the position of ampicillin/sulbactam

Ampicillin/Sulbactam in Combination: A Review of its Use in the Treatment of Severe Bacterial Infections

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients

Contact Info

Product

Resources

About